Kwality Pharmaceuticals Raises FY27 Target Above ₹700 Crore

Kwality Pharmaceuticals Ltd raised its FY27 revenue target to above ₹700 crore after reporting Q1 FY27 revenue of ₹162.35 crore, up 45.63% year-on-year, while net profit rose 114.93% to ₹25.62 crore for the quarter ended June 30, 2026.

What did Kwality Pharma report for Q1 FY27?

Kwality Pharma reported higher revenue and profit in the June 2026 quarter, supported by year-on-year growth in its pharmaceutical business. Revenue from operations stood at ₹162.35 crore, compared with ₹111.48 crore in Q1 FY26, representing growth of 45.63%. Revenue also rose 3.34% sequentially from ₹157.11 crore in Q4 FY26.

Profit before tax increased to ₹33.98 crore, up 99.53% from the year-earlier quarter and 7.33% from ₹31.66 crore in the preceding quarter. Net profit was ₹25.62 crore, compared with ₹11.92 crore a year earlier. This translated into year-on-year net profit growth of 114.93%, while sequential net profit increased 1.22% from ₹25.31 crore.

The company’s reported profitability metrics also improved. EBITDA was stated at about ₹41 crore for Q1 FY27, while EBITDA margin expanded to 25.3% from 21.9% in Q1 FY26. Net profit margin rose to about 15.7% from 10.7% a year earlier, reflecting the sharper rise in profit relative to revenue.

Why did Kwality Pharma raise its FY27 guidance?

Kwality Pharma raised its FY27 revenue guidance after the June-quarter performance and management’s assessment of its business pipeline. The company now expects FY27 revenue to exceed ₹700 crore, compared with an earlier target range of ₹650 crore to ₹700 crore. Other material from the company referred to a prior ₹600 crore target, but the latest stated guidance is above ₹700 crore.

Management linked the revised outlook to registrations for niche injectable products in Latin America and the Middle East and North Africa region. The company has also identified biosimilars, hormones and complex injectables as areas of focus. These categories form part of the stated strategy to expand its product reach and build a larger revenue base.

The profitability outlook was also revised upward in some company updates. Kwality Pharma guided for FY27 EBITDA of ₹189 crore to ₹196 crore or more, implying an EBITDA margin of 27% to 28% or higher. Earlier call-related disclosures cited an EBITDA margin range of 26% to 27%, making the later 27% to 28% or higher guidance the more expansive stated outlook.

How does the Q1 performance compare with Kwality Pharma’s recent growth?

Kwality Pharma entered FY27 after reporting FY26 revenue of ₹503 crore, up 36% from ₹370 crore in FY25. The first-quarter revenue of ₹162.35 crore represents a higher quarterly sales base than the ₹111 crore to ₹123 crore range reported in several quarters during FY25 and the ₹157 crore recorded in Q4 FY26.

The June-quarter result also indicates that profitability growth exceeded revenue growth on a year-on-year basis. Revenue increased 45.63%, whereas net profit increased 114.93%. The improvement in EBITDA and net profit margins is significant because management’s full-year plan is based not only on higher sales but also on sustaining stronger operating profitability.

Management noted that gross margin was about 53% in the latest quarter, compared with roughly 56% to 57% in the prior quarter. Even with that movement, the reported EBITDA margin was higher year-on-year. The available disclosures do not provide a detailed product-wise or geography-wise revenue break-up to quantify the contribution from individual export markets or therapeutic categories.

What should investors watch after the revised FY27 target?

Investors will focus on whether quarterly revenue and margins remain aligned with the revised full-year targets. Revenue of more than ₹700 crore would require a substantially larger annual sales base than FY26 revenue of ₹503 crore. The company has framed registrations and expansion in niche injectable markets as key operational drivers of that plan.

The next scheduled disclosure is the Q2 FY27 financial results for the quarter and half year ended September 30, 2026. Kwality Pharma scheduled a board meeting on November 12, 2026 to consider the unaudited standalone and consolidated results. It also scheduled an earnings conference call for November 13, 2026 at 4:00 PM IST, with pre-registration required.

The Q2 release and management call are relevant for assessing progress on the revised guidance, margin trajectory and the development of the injectable product pipeline. They may also provide more clarity on the pace of registrations in Latin America and the Middle East and North Africa, where the company has identified opportunities.

Conclusion

Kwality Pharma’s Q1 FY27 results showed a 45.63% increase in revenue to ₹162.35 crore and a 114.93% rise in net profit to ₹25.62 crore. The outcome led management to raise its FY27 revenue objective to above ₹700 crore and set a higher stated EBITDA outlook of ₹189 crore to ₹196 crore or more.

The immediate item to watch is the Q2 FY27 result and the November 13, 2026 earnings call. Investors will look for management’s updates on revenue conversion, the stated 27% to 28% or higher EBITDA margin objective, and progress in niche injectable registrations across international markets.